<img src="https://trc.taboola.com/1321591/log/3/unip?en=page_view" width="0" height="0" style="display:none">
Fact Check Library

Fact Check with Logically.

Download the Free App Today

true
true

CLAIM ID

766dd195

The Singapore REIT market outperformed the Singapore stock exchange in 2020-2021.

Singapore REITs outperformed the Stock Exchange in 2021, with total returns of 5.1 percent and a market value of S$106 billion.

Singapore REITs outperformed the Stock Exchange in 2021, with total returns of 5.1 percent and a market value of S$106 billion. A real estate investment trust in Singapore (S-REIT) is a fund on the Stock Exchange (SGX) that invests in a portfolio of real estate assets such as shopping malls, offices, and hotels. Singapore is renowned as one of the largest and fastest-growing REIT markets in the Asia Pacific, with market size of over S$110 billion. It grew at a compound annual growth rate (CAGR) of 11 percent between 2010 and 2020.

S-REITs market offers the highest dividend yield of 5.1 percent compared with other major asset classes in Singapore. In terms of performance, over the last ten years, S-REITs have averaged an annualized total return of 10.7 percent and 90-day volatility of 10.5 percent, which is competitive among significant equity indexes.

S-REITs continued to maintain turnover growth in 2020, with 43 property trusts generating 26 percent of the stock market’s S$1.23 billion average daily turnovers, whereas the REIT Sector contributed 24 percent to Singapore’s overall stock market turnover in 2019.

A yearly statistical data released by the REIT Association of Singapore shows that S-REITs performance is way beyond the stock exchange (SGX), so we see this claim as accurate.

Have a question or correction on one of our fact-checks?

If you think a claim has been misjudged or requires correction, please send us evidence to support your error claim. We will revisit our evidence and verdict and conduct additional research to verify new information.

Fact Check of the Day

misleading

397 children were diagnosed with heart inflammation after receiving Pfizer’s COVID-19 vaccine in U.S.